February 12, 2024 11:16 AM EST
News Briefing

Im­muno­van­t's plans for au­toim­mune as­set; Wall Street wor­ries about Mod­er­na’s RSV can­di­date 

Max Gelman

Senior Editor

Ayisha Sharma

News Reporter

Jaimy Lee

Deputy Editor

Plus, news about No­vo Hold­ings, Grit­stone Bio, In­vivyd and Sci­ence 37:

Im­muno­vant out­lines big plans for its au­toim­mune pro­gram: The biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times